Literature DB >> 17658239

Catecholaminergic neuronal loss in locus coeruleus of aged female dtg APP/PS1 mice.

Jahn N O'Neil1, Peter R Mouton, Yousef Tizabi, Mary Ann Ottinger, De-Liang Lei, Donald K Ingram, Kebreten F Manaye.   

Abstract

Alzheimer's disease (AD) is the most common type of dementia afflicting the elderly. In addition to the presence of cortical senile plaques and neurofibrillary tangles, AD is characterized at autopsy by extensive degeneration of brainstem locus coeruleus (LC) neurons that provide noradrenergic innervation to cortical neuropil, together with relative stability of dopaminergic neuron number in substantia nigra (SN) and ventral tegmental area (VTA). The present study used design-based stereological methods to assess catecholaminergic neuronal loss in brains of double transgenic female mice that co-express two human mutations associated with familial AD, amyloid precursor protein (APP(swe)) and presenilin-1 (PS1(DeltaE9)). Mice were analyzed at two age groups, 3-6 months and 16-23 months, when deposition of AD-type beta-amyloid (Abeta) plaques occurs in cortical brain regions. Blocks of brain tissue containing the noradrenergic LC nucleus and two nuclei of dopaminergic neurons, the SN and VTA, were sectioned and sampled in a systematic-random manner and immunostained for tyrosine hydroxylase (TH), a specific marker for catecholaminergic neurons. Using the optical fractionator method we found a 24% reduction in the total number of TH-positive neurons in LC with no changes in SN-VTA of aged dtg APP/PS1 mice compared with non-transgenic controls. No significant differences were observed in numbers of TH-positive neurons in LC or SN-VTA in brains of young female dtg APP/PS1 mice compared to their age-matched controls. The findings of selective neurodegeneration of LC neurons in the brains of aged female dtg APP/PS1 mice mimic the neuropathology in the brains of AD patients at autopsy. These findings support the use of murine models of Abeta deposition to develop novel strategies for the therapeutic management of patients afflicted with AD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17658239      PMCID: PMC5483173          DOI: 10.1016/j.jchemneu.2007.05.008

Source DB:  PubMed          Journal:  J Chem Neuroanat        ISSN: 0891-0618            Impact factor:   3.052


  58 in total

1.  The efficiency of systematic sampling in stereology--reconsidered.

Authors:  H J Gundersen; E B Jensen; K Kiêu
Journal:  J Microsc       Date:  1999-03       Impact factor: 1.758

2.  Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections.

Authors:  H Braak; E Braak
Journal:  Brain Pathol       Date:  1991-04       Impact factor: 6.508

3.  Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease.

Authors:  K Johnson-Wood; M Lee; R Motter; K Hu; G Gordon; R Barbour; K Khan; M Gordon; H Tan; D Games; I Lieberburg; D Schenk; P Seubert; L McConlogue
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

4.  Lack of beta-amyloidosis in transgenic mice expressing low levels of familial Alzheimer's disease missense mutations.

Authors:  P Malherbe; J G Richards; J R Martin; H Bluethmann; J Maggio; G Huber
Journal:  Neurobiol Aging       Date:  1996 Mar-Apr       Impact factor: 4.673

5.  Incidence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group.

Authors:  L Fratiglioni; L J Launer; K Andersen; M M Breteler; J R Copeland; J F Dartigues; A Lobo; J Martinez-Lage; H Soininen; A Hofman
Journal:  Neurology       Date:  2000       Impact factor: 9.910

6.  Very old women at highest risk of dementia and Alzheimer's disease: incidence data from the Kungsholmen Project, Stockholm.

Authors:  L Fratiglioni; M Viitanen; E von Strauss; V Tontodonati; A Herlitz; B Winblad
Journal:  Neurology       Date:  1997-01       Impact factor: 9.910

7.  Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes.

Authors:  L Holcomb; M N Gordon; E McGowan; X Yu; S Benkovic; P Jantzen; K Wright; I Saad; R Mueller; D Morgan; S Sanders; C Zehr; K O'Campo; J Hardy; C M Prada; C Eckman; S Younkin; K Hsiao; K Duff
Journal:  Nat Med       Date:  1998-01       Impact factor: 53.440

8.  The neuropathology of aminergic nuclei in Alzheimer's disease.

Authors:  R M Zweig; C A Ross; J C Hedreen; C Steele; J E Cardillo; P J Whitehouse; M F Folstein; D L Price
Journal:  Ann Neurol       Date:  1988-08       Impact factor: 10.422

9.  Neuron loss in key cholinergic and aminergic nuclei in Alzheimer disease: a meta-analysis.

Authors:  Scott A Lyness; Chris Zarow; Helena C Chui
Journal:  Neurobiol Aging       Date:  2003 Jan-Feb       Impact factor: 4.673

10.  Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein.

Authors:  D Games; D Adams; R Alessandrini; R Barbour; P Berthelette; C Blackwell; T Carr; J Clemens; T Donaldson; F Gillespie
Journal:  Nature       Date:  1995-02-09       Impact factor: 49.962

View more
  31 in total

1.  Age-related loss of noradrenergic neurons in the brains of triple transgenic mice.

Authors:  Kebreten F Manaye; Peter R Mouton; Guang Xu; Amy Drew; De-Liang Lei; Yukti Sharma; G William Rebeck; Scott Turner
Journal:  Age (Dordr)       Date:  2011-11-30

2.  Allopregnanolone increases the number of dopaminergic neurons in substantia nigra of a triple transgenic mouse model of Alzheimer's disease.

Authors:  Chenyou Sun; Xiaoming Ou; Jerry M Farley; Craig Stockmeier; Steven Bigler; Roberta Diaz Brinton; Jun Ming Wang
Journal:  Curr Alzheimer Res       Date:  2012-05       Impact factor: 3.498

3.  A noradrenergic lesion exacerbates neurodegeneration in a Down syndrome mouse model.

Authors:  Jason Lockrow; Heather Boger; Greg Gerhardt; Gary Aston-Jones; David Bachman; Ann-Charlotte Granholm
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

4.  The effects of age and lipopolysaccharide (LPS)-mediated peripheral inflammation on numbers of central catecholaminergic neurons.

Authors:  P R Mouton; B Kelley-Bell; D Tweedie; E L Spangler; E Perez; O D Carlson; R G Short; R deCabo; J Chang; D K Ingram; Y Li; N H Greig
Journal:  Neurobiol Aging       Date:  2010-11-19       Impact factor: 4.673

5.  Neuropathological quantification of dtg APP/PS1: neuroimaging, stereology, and biochemistry.

Authors:  Kebreten F Manaye; Paul C Wang; Jahn N O'Neil; Sophia Y Huang; Tao Xu; De-Liang Lei; Yousef Tizabi; Mary Ann Ottinger; Donald K Ingram; Peter R Mouton
Journal:  Age (Dordr)       Date:  2007-08-03

6.  Locus coeruleus damage and noradrenaline reductions in multiple sclerosis and experimental autoimmune encephalomyelitis.

Authors:  Paul E Polak; Sergey Kalinin; Douglas L Feinstein
Journal:  Brain       Date:  2011-02-04       Impact factor: 13.501

7.  Endogenous signaling through alpha7-containing nicotinic receptors promotes maturation and integration of adult-born neurons in the hippocampus.

Authors:  Nolan R Campbell; Catarina C Fernandes; Andrew W Halff; Darwin K Berg
Journal:  J Neurosci       Date:  2010-06-30       Impact factor: 6.167

8.  Ear2 deletion causes early memory and learning deficits in APP/PS1 mice.

Authors:  Markus P Kummer; Thea Hammerschmidt; Ana Martinez; Dick Terwel; Gregor Eichele; Anika Witten; Stefanie Figura; Monika Stoll; Stephanie Schwartz; Hans-Christian Pape; Joachim L Schultze; David Weinshenker; Michael T Heneka; Inga Urban
Journal:  J Neurosci       Date:  2014-06-25       Impact factor: 6.167

9.  Caloric restriction attenuates amyloid deposition in middle-aged dtg APP/PS1 mice.

Authors:  Peter R Mouton; Mark E Chachich; Christopher Quigley; Edward Spangler; Donald K Ingram
Journal:  Neurosci Lett       Date:  2009-08-20       Impact factor: 3.046

10.  Selective loss of noradrenaline exacerbates early cognitive dysfunction and synaptic deficits in APP/PS1 mice.

Authors:  Thea Hammerschmidt; Markus P Kummer; Dick Terwel; Ana Martinez; Ali Gorji; Hans-Christian Pape; Karen S Rommelfanger; Jason P Schroeder; Monika Stoll; Joachim Schultze; David Weinshenker; Michael T Heneka
Journal:  Biol Psychiatry       Date:  2012-08-09       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.